SAN DIEGO--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today announced results for LGD-4665 from multiple Phase I clinical trials and interim findings from a Phase II trial in ITP patients in a poster presentation at the American Society of Hematology (ASH) 50th Annual Meeting, being held at the Moscone Center in San Francisco on December 6-9, 2008. Poster III-488 (Abstract 3406) will be presented from 5:30 to 7:30 pacific time in Hall A. The poster presentation can be viewed by visiting the Investor Relations section of Ligand’s website at www.ligand.com.
